Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies

Authors
Publication date
1 January 2013
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ghent University Academic Bibliography

    redirect
    oaioai:archive.ugent.be:5792523
    Last time updated on 12/11/2016